Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Alvimopan | hsa00071 | Fatty acid degradation | 4.66E-02 | 3 | O75521, P11766, P33121 | ECI2, ADH5, ACSL1 | More | | Alvimopan | hsa00190 | Oxidative phosphorylation | 1.00E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Alvimopan | hsa00230 | Purine metabolism | 1.56E-02 | 3 | Q7LG56, P51828, Q9Y227 | RRM2B, ADCY7, ENTPD4 | More | | Alvimopan | hsa00240 | Pyrimidine metabolism | 1.45E-02 | 2 | Q7LG56, Q9Y227 | RRM2B, ENTPD4 | More | | Alvimopan | hsa00280 | Valine, leucine and isoleucine degradation | 4.31E-02 | 2 | P26440, Q02252 | IVD, ALDH6A1 | More | | Alvimopan | hsa00500 | Starch and sucrose metabolism | 9.22E-04 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Alvimopan | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Alvimopan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Alvimopan | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | Alvimopan | hsa00600 | Sphingolipid metabolism | 2.68E-02 | 2 | P07602, Q13510 | PSAP, ASAH1 | More | | Alvimopan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 2.48E-02 | 2 | P40926, P15104 | MDH2, GLUL | More | | Alvimopan | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Alvimopan | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Alvimopan | hsa00830 | Retinol metabolism | 4.55E-02 | 1 | P00325 | ADH1B | More | | Alvimopan | hsa00860 | Porphyrin and chlorophyll metabolism | 5.29E-03 | 2 | P53004, P30043 | BLVRA, BLVRB | More | | Alvimopan | hsa00920 | Sulfur metabolism | 1.78E-02 | 1 | Q16762 | TST | More | | Alvimopan | hsa00970 | Aminoacyl-tRNA biosynthesis | 9.22E-06 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Alvimopan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Alvimopan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Alvimopan | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Alvimopan | hsa03008 | Ribosome biogenesis in eukaryotes | 2.60E-03 | 5 | Q9NYH9, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Alvimopan | hsa03013 | RNA transport | 1.78E-06 | 19 | O14980, P52298, Q09161, O14893, P61326, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, O75822, P78345, P20042, Q14240, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF3J, RPP38, EIF2S2, EIF4A2, TACC3, FXR1 | More | | Alvimopan | hsa03040 | Spliceosome | 1.91E-09 | 21 | Q14562, O43143, O60508, Q99633, P17844, P08579, Q15427, P26368, P51991, P38159, P61978, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, DDX5, SNRPB2, SF3B4, U2AF2, HNRPA3, RBMX, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, PPIH, ASCC3L1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P46091 | GPR1 | Chemerin-like receptor 2 | Q14562 | DHX8 | ATP-dependent RNA helicase DHX8 | -0.819 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.76 | P46091 | GPR1 | Chemerin-like receptor 2 | O43143 | DHX15 | ATP-dependent RNA helicase DHX15 | -0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.812 | P46091 | GPR1 | Chemerin-like receptor 2 | O60508 | CDC40 | Pre-mRNA-processing factor 17 | -0.778 | P46091 | GPR1 | Chemerin-like receptor 2 | Q99633 | PRPF18 | Pre-mRNA-splicing factor 18 | -0.711 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P17844 | DDX5 | Probable ATP-dependent RNA helicase DDX5 | 0.73 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08579 | SNRPB2 | U2 small nuclear ribonucleoprotein B'' | -0.822 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q15427 | SF3B4 | Splicing factor 3B subunit 4 | 0.71 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P26368 | U2AF2 | Splicing factor U2AF 65 kDa subunit | -0.751 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P51991 | HNRPA3 | Heterogeneous nuclear ribonucleoprotein A3 | 0.787 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P38159 | RBMX | RNA-binding motif protein, X chromosome | 0.733 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P61978 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 0.827 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P61978 | HNRPK | Heterogeneous nuclear ribonucleoprotein K | 0.784 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.74 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13595 | TRA2A | Transformer-2 protein homolog alpha | -0.753 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q07955 | SFRS1 | Serine/arginine-rich splicing factor 1 | -0.749 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.798 | P46091 | GPR1 | Chemerin-like receptor 2 | Q01130 | SFRS2 | Serine/arginine-rich splicing factor 2 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84103 | SFRS3 | Serine/arginine-rich splicing factor 3 | -0.773 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13243 | SFRS5 | Serine/arginine-rich splicing factor 5 | -0.822 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UMS4 | PRPF19 | Pre-mRNA-processing factor 19 | 0.703 | P07900 | HSP90AA1 | Heat shock protein HSP 90-alpha | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.709 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | 0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P11142 | HSPA8 | Heat shock cognate 71 kDa protein | -0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q9Y2W2 | WBP11 | WW domain-binding protein 11 | -0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O43447 | PPIH | Peptidyl-prolyl cis-trans isomerase H | -0.766 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75643 | ASCC3L1 | U5 small nuclear ribonucleoprotein 200 kDa helicase | -0.745 |
| Alvimopan | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Alvimopan | hsa03450 | Non-homologous end-joining | 4.32E-02 | 1 | Q9NP87 | POLM | More | | Alvimopan | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Alvimopan | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Alvimopan | hsa04015 | Rap1 signaling pathway | 1.06E-04 | 14 | P20827, P49767, P63261, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P0DP23, P08514, P17252, P19174 | EFNA1, VEGFC, ACTG1, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, CALM1, ITGA2B, PRKCA, PLCG1 | More | | Alvimopan | hsa04020 | Calcium signaling pathway | 2.59E-06 | 12 | Q96DU7, P45880, Q16566, Q13557, P17252, P21860, O15399, P25116, P0DP23, P51828, P23634, P49767 | ITPKC, VDAC2, CAMK4, CAMK2D, PRKCA, ERBB3, GRIN2D, F2R, CALM1, ADCY7, ATP2B4, VEGFC | More | | Alvimopan | hsa04022 | cGMP-PKG signaling pathway | 1.58E-03 | 7 | P24844, Q99941, P23634, Q8WYR1, P51828, P45880, Q15746 | MYL9, CREBL1, ATP2B4, PIK3R5, ADCY7, VDAC2, MYLK | More | | Alvimopan | hsa04024 | cAMP signaling pathway | 1.71E-03 | 7 | P0DP23, P23634, Q16566, P48058, O15399, P25116, P24844 | CALM1, ATP2B4, CAMK4, GRIA4, GRIN2D, F2R, MYL9 | More | | Alvimopan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Alvimopan | hsa04062 | Chemokine signaling pathway | 9.51E-06 | 19 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.803 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.864 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Alvimopan | hsa04064 | NF-kappa B signaling pathway | 3.08E-03 | 13 | P10415, P51617, Q13546, P14778, P19174, Q04759, Q9UDY8, Q13077, P06239, P24522, P09341, P19875, Q06643 | BCL2, IRAK1, RIPK1, IL1R1, PLCG1, PRKCQ, MALT1, TRAF1, LCK, GADD45A, CXCL1, CXCL2, LTB | More | | Alvimopan | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Alvimopan | hsa04071 | Sphingolipid signaling pathway | 2.11E-04 | 10 | P17252, Q9H228, P01375, Q13510, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, EDG8, TNF, ASAH1, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | Alvimopan | hsa04072 | Phospholipase D signaling pathway | 7.43E-03 | 8 | P42338, Q9UQC2, P43657, P25024, P25025, P19174, Q8WYR1, Q08828 | PIK3CB, GAB2, P2RY5, CXCR1, CXCR2, PLCG1, PIK3R5, ADCY1 | More | | Alvimopan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Alvimopan | hsa04122 | Sulfur relay system | 1.78E-02 | 1 | Q16762 | TST | More | | Alvimopan | hsa04136 | Autophagy - other | 3.53E-02 | 1 | O94817 | ATG12 | More | | Alvimopan | hsa04141 | Protein processing in endoplasmic reticulum | 2.94E-04 | 8 | P18848, Q15437, Q99941, O75460, P11142, Q9H3Z4, P07900, Q9NR31 | ATF4, SEC23B, CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1, SAR1A | More | | Alvimopan | hsa04142 | Lysosome | 2.23E-02 | 4 | P22304, Q13510, Q04900, Q9Y227 | IDS, ASAH1, CD164, ENTPD4 | More | | Alvimopan | hsa04144 | Endocytosis | 2.57E-03 | 6 | O75351, P62491, P42566, Q15438, Q14161, Q9UNH7 | VPS4B, RAB11A, EPS15, PSCD1, GIT2, SNX6 | More | | Alvimopan | hsa04145 | Phagosome | 1.86E-02 | 5 | P63261, Q15080, Q13509, P68371, P27824 | ACTG1, NCF4, TUBB3, TUBB2C, CANX | More | | Alvimopan | hsa04151 | PI3K-Akt signaling pathway | 1.43E-04 | 23 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, Q13362, P07900, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P22105, P14784, P23458, Q99941, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, PPP2R5C, HSP90AA1, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, TNXB, IL2RB, JAK1, CREBL1, ATF4, SGK, PIK3AP1, CCND3 | More | | Alvimopan | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Alvimopan | hsa04213 | Longevity regulating pathway - multiple species | 1.41E-04 | 6 | P42338, Q9Y4H2, Q08828, P0DMV8, P11142, Q13547 | PIK3CB, IRS2, ADCY1, HSPA1A, HSPA8, HDAC1 | More | | Alvimopan | hsa04217 | Necroptosis | 2.24E-04 | 12 | P01375, P01568, P48023, Q13489, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | Alvimopan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.68E-04 | 10 | P51828, Q99941, P18848, Q16537, P0DP23, Q13557, P17252, P10415, P20020, P23634 | ADCY7, CREBL1, ATF4, PPP2R5E, CALM1, CAMK2D, PRKCA, BCL2, ATP2B1, ATP2B4 | More | | Alvimopan | hsa04270 | Vascular smooth muscle contraction | 2.56E-03 | 5 | Q15746, P24844, Q08828, P35579, P35318 | MYLK, MYL9, ADCY1, MYH9, ADM | More | | Alvimopan | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Alvimopan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Alvimopan | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Alvimopan | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Alvimopan | hsa04390 | Hippo signaling pathway | 1.47E-02 | 5 | P63261, Q13485, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, LEF1, SNAI2, BIRC3 | More | | Alvimopan | hsa04510 | Focal adhesion | 3.90E-03 | 9 | P08514, Q15746, P24844, Q15942, P17252, Q13489, P10415, P49767, P63261 | ITGA2B, MYLK, MYL9, ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Alvimopan | hsa04512 | ECM-receptor interaction | 2.44E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Alvimopan | hsa04514 | Cell adhesion molecules | 2.58E-03 | 2 | P16109, O00501 | SELP, CLDN5 | More | | Alvimopan | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Alvimopan | hsa04530 | Tight junction | 1.18E-05 | 6 | Q8TEU7, P16989, P56750, O00501, Q14247, P24844 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN, MYL9 | More | | Alvimopan | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Alvimopan | hsa04610 | Complement and coagulation cascades | 2.94E-02 | 2 | P25116, P10909 | F2R, CLU | More | | Alvimopan | hsa04611 | Platelet activation | 1.55E-06 | 7 | P25116, Q9Y490, P08514, Q15746, Q08828, Q8WYR1, P07359 | F2R, TLN1, ITGA2B, MYLK, ADCY1, PIK3R5, GP1BA | More | | Alvimopan | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | Alvimopan | hsa04613 | Neutrophil extracellular trap formation | 1.80E-05 | 17 | P17252, P11215, O60603, P08246, Q13547, Q92769, Q6FI13, Q93077, P58876, P62807, P33778, Q16778, O60814, P68431, P14598, Q15080, P21462 | PRKCA, ITGAM, TLR2, ELA2, HDAC1, HDAC2, H2AC18; H2AC19, HIST1H2AC, H2BC5, HIST1H2BC, H2BC3, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, FPR1 | More | | Alvimopan | hsa04614 | Renin-angiotensin system | 1.52E-02 | 1 | P50052 | AGTR2 | More | | Alvimopan | hsa04621 | NOD-like receptor signaling pathway | 3.19E-02 | 3 | P23458, Q9H3M7, P43490 | JAK1, TXNIP, PBEF1 | More | | Alvimopan | hsa04623 | Cytosolic DNA-sensing pathway | 3.15E-02 | 2 | P01568, P25963 | IFNA21, NFKBIA | More | | Alvimopan | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Alvimopan | hsa04650 | Natural killer cell mediated cytotoxicity | 6.78E-07 | 13 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Alvimopan | hsa04658 | Th1 and Th2 cell differentiation | 2.21E-04 | 8 | Q04759, P07766, P20963, P19174, P06239, Q9UL17, P14784, Q13761 | PRKCQ, CD3E, CD247, PLCG1, LCK, TBX21, IL2RB, RUNX3 | More | | Alvimopan | hsa04659 | Th17 cell differentiation | 9.05E-05 | 11 | Q04759, P19174, P06239, P14784, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P20963 | PRKCQ, PLCG1, LCK, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | Alvimopan | hsa04660 | T cell receptor signaling pathway | 2.21E-05 | 14 | P01375, Q04759, P42338, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Alvimopan | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Alvimopan | hsa04664 | Fc epsilon RI signaling pathway | 3.40E-03 | 6 | P42338, Q9UQC2, P07948, P19174, P09917, P20292 | PIK3CB, GAB2, LYN, PLCG1, ALOX5, ALOX5AP | More | | Alvimopan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Alvimopan | hsa04668 | TNF signaling pathway | 4.74E-02 | 3 | Q99941, P01584, O95429 | CREBL1, IL1B, BAG4 | More | | Alvimopan | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | | Alvimopan | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | Alvimopan | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | Alvimopan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Alvimopan | hsa04724 | Glutamatergic synapse | 2.94E-02 | 2 | P48058, Q9NSB8 | GRIA4, HOMER2 | More | | Alvimopan | hsa04725 | Cholinergic synapse | 2.17E-02 | 3 | P51828, P18848, Q13557 | ADCY7, ATF4, CAMK2D | More | | Alvimopan | hsa04728 | Dopaminergic synapse | 4.12E-03 | 9 | P14416, P63218, P50151, P49841, Q99941, P18848, Q16539, Q13557, P49407 | DRD2, GNG5, GNG10, GSK3B, CREBL1, ATF4, MAPK14, CAMK2D, ARRB1 | More | | Alvimopan | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.62E-04 | 8 | P14778, P01584, P51828, Q13557, P19174, P42338, P24723, Q04759 | IL1R1, IL1B, ADCY7, CAMK2D, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Alvimopan | hsa04810 | Regulation of actin cytoskeleton | 1.38E-03 | 4 | P24844, Q15746, P08514, P25116 | MYL9, MYLK, ITGA2B, F2R | More | | Alvimopan | hsa04911 | Insulin secretion | 2.03E-05 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Alvimopan | hsa04912 | GnRH signaling pathway | 2.94E-04 | 8 | P17252, P51828, P18848, Q13557, Q14643, P0DP24, P0DP23, P45985 | PRKCA, ADCY7, ATF4, CAMK2D, ITPR1, CALM2, CALM1, MAP2K4 | More | | Alvimopan | hsa04915 | Estrogen signaling pathway | 1.68E-05 | 8 | Q99941, P18848, Q08828, P51828, P07900, P0DMV8, P11142, Q15788 | CREBL1, ATF4, ADCY1, ADCY7, HSP90AA1, HSPA1A, HSPA8, NCOA1 | More | | Alvimopan | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Alvimopan | hsa04918 | Thyroid hormone synthesis | 1.69E-03 | 4 | P51828, Q99941, P18848, P02768 | ADCY7, CREBL1, ATF4, ALB | More | | Alvimopan | hsa04921 | Oxytocin signaling pathway | 1.65E-04 | 9 | Q15746, P0DP23, Q08828, P17252, Q16566, P24844, P63261, Q96RR4, Q8WYR1 | MYLK, CALM1, ADCY1, PRKCA, CAMK4, MYL9, ACTG1, CAMKK2, PIK3R5 | More | | Alvimopan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Alvimopan | hsa04925 | Aldosterone synthesis and secretion | 5.06E-08 | 10 | Q14643, Q99941, P18848, P51828, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ATF4, ADCY7, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Alvimopan | hsa04926 | Relaxin signaling pathway | 3.34E-02 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Alvimopan | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Alvimopan | hsa04928 | Parathyroid hormone synthesis, secretion and action | 2.17E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Alvimopan | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | | Alvimopan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.93E-03 | 7 | P84022, Q13485, P10415, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Alvimopan | hsa04934 | Cushing syndrome | 1.09E-05 | 5 | Q99941, P18848, P51828, O15169, Q13557 | CREBL1, ATF4, ADCY7, AXIN1, CAMK2D | More | | Alvimopan | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Alvimopan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Alvimopan | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Alvimopan | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | Alvimopan | hsa04970 | Salivary secretion | 1.01E-04 | 7 | P51828, Q14643, P20020, P23634, P17252, P0DP24, P0DP23 | ADCY7, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM2, CALM1 | More | | Alvimopan | hsa04971 | Gastric acid secretion | 1.87E-03 | 6 | P51828, P17252, P15311, P63261, P0DP23, Q13557 | ADCY7, PRKCA, VIL2, ACTG1, CALM1, CAMK2D | More | | Alvimopan | hsa04972 | Pancreatic secretion | 2.15E-03 | 5 | Q14643, P20020, P17252, Q08828, P62491 | ITPR1, ATP2B1, PRKCA, ADCY1, RAB11A | More | | Alvimopan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Alvimopan | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Alvimopan | hsa05010 | Alzheimer disease | 2.07E-02 | 7 | Q92542, P05496, P12074, O75460, P01584, O15169, P45880 | NCSTN, ATP5G1, COX6A1, ERN1, IL1B, AXIN1, VDAC2 | More | | Alvimopan | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Alvimopan | hsa05020 | Prion disease | 1.81E-02 | 7 | P01584, P46531, P11142, P05496, P12074, P45880, Q99941 | IL1B, NOTCH1, HSPA8, ATP5G1, COX6A1, VDAC2, CREBL1 | More | | Alvimopan | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Alvimopan | hsa05031 | Amphetamine addiction | 2.72E-04 | 7 | O15399, P0DP23, Q16566, Q13557, Q99941, P18848, P17252 | GRIN2D, CALM1, CAMK4, CAMK2D, CREBL1, ATF4, PRKCA | More | | Alvimopan | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Alvimopan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.62E-04 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Alvimopan | hsa05130 | Pathogenic Escherichia coli infection | 2.51E-02 | 3 | Q14247, O00501, P25116 | CTTN, CLDN5, F2R | More | | Alvimopan | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Alvimopan | hsa05133 | Pertussis | 2.52E-02 | 3 | P0DP23, P23528, P09871 | CALM1, CFL1, C1S | More | | Alvimopan | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Alvimopan | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Alvimopan | hsa05140 | Leishmaniasis | 6.62E-04 | 8 | P14598, P42224, O60603, P25963, P29350, P49006, P51617, Q15080 | NCF1, STAT1, TLR2, NFKBIA, PTPN6, MARCKSL1, IRAK1, NCF4 | More | | Alvimopan | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | | Alvimopan | hsa05144 | Malaria | 1.64E-03 | 5 | P60033, O60603, P01375, P35443, P26718 | CD81, TLR2, TNF, THBS4, KLRK1 | More | | Alvimopan | hsa05145 | Toxoplasmosis | 6.86E-03 | 3 | P23458, Q8WYR1, P0DMV8 | JAK1, PIK3R5, HSPA1A | More | | Alvimopan | hsa05146 | Amoebiasis | 2.21E-04 | 8 | P09341, P19875, P14778, P27930, P42338, P11215, P05089, P12814 | CXCL1, CXCL2, IL1R1, IL1R2, PIK3CB, ITGAM, ARG1, ACTN1 | More | | Alvimopan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Alvimopan | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Alvimopan | hsa05162 | Measles | 2.68E-02 | 2 | P23458, P0DMV8 | JAK1, HSPA1A | More | | Alvimopan | hsa05163 | Human cytomegalovirus infection | 1.72E-02 | 8 | P01375, P63218, P50151, P49841, P14778, P25025, Q16539, O00463 | TNF, GNG5, GNG10, GSK3B, IL1R1, CXCR2, MAPK14, TRAF5 | More | | Alvimopan | hsa05168 | Herpes simplex virus 1 infection | 2.31E-04 | 17 | Q9UKJ0, P25963, P01568, Q05823, Q9GZY0, P42224, Q07955, Q01130, Q13243, Q13489, Q13398, Q9HCX3, Q03923, P52738, O75820, Q9UDV6, P10415 | PILRB, NFKBIA, IFNA21, RNASEL, NXF2; NXF2B, STAT1, SFRS1, SFRS2, SFRS5, BIRC3, ZNF211, ZNF304, ZNF85, ZNF140, ZNF189, ZNF212, BCL2 | More | | Alvimopan | hsa05169 | Epstein-Barr virus infection | 2.54E-02 | 8 | Q92769, P04637, Q13546, P10415, P24522, O60603, P51617, P09693 | HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, IRAK1, CD3G | More | | Alvimopan | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | Alvimopan | hsa05200 | Pathways in cancer | 5.18E-04 | 26 | Q13751, P42338, P08238, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P49767, P43657, P25116, P63218, P50151, Q14344, Q7LDG7, P78417, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, VEGFC, P2RY5, F2R, GNG5, GNG10, GNA13, RASGRP2, GSTO1, GADD45B, CALM1, IFNA21, IL2RB | More | | Alvimopan | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | Alvimopan | hsa05203 | Viral carcinogenesis | 9.17E-05 | 10 | Q99941, P18848, P27348, Q13547, Q15283, P61978, P58876, P62807, Q16778, O60814 | CREBL1, ATF4, YWHAQ, HDAC1, RASA2, HNRPK, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | Alvimopan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Alvimopan | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Alvimopan | hsa05212 | Pancreatic cancer | 9.39E-03 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Alvimopan | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | Alvimopan | hsa05216 | Thyroid cancer | 1.85E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Alvimopan | hsa05217 | Basal cell carcinoma | 4.42E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Alvimopan | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Alvimopan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.27E-03 | 6 | P42338, P19174, P07766, P20963, P06239, Q04759 | PIK3CB, PLCG1, CD3E, CD247, LCK, PRKCQ | More | | Alvimopan | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Alvimopan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Alvimopan | hsa05332 | Graft-versus-host disease | 3.70E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Alvimopan | hsa05415 | Diabetic cardiomyopathy | 1.07E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | | Alvimopan | hsa05418 | Fluid shear stress and atherosclerosis | 2.49E-03 | 11 | Q16539, P78417, P10599, P14780, P01375, P63261, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |